File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B

Title96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B
Authors
KeywordsAdefovir dipivoxil
Adefovir dipivoxil plus emtricitabine
Combination therapy
Normalization of serum alanine aminotransaminase
Serum HBV DNA suppression
Issue Date2008
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
Journal Of Hepatology, 2008, v. 48 n. 5, p. 714-720 How to Cite?
AbstractBackground/Aims: In order to prevent the occurrence of drug-resistant mutants associated with treatment for chronic hepatitis B virus (HBV) infection, combination therapy is being developed. To determine the efficacy of adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy in chronic HBV infection. Methods: Thirty treatment-nai{dotless}̈ve, HBeAg-positive patients were randomized to combination ADV plus FTC (n = 14) or ADV plus placebo monotherapy (n = 16) for 96 weeks. HBV DNA was measured by polymerase chain reaction. Treatment was stopped in those with HBeAg seroconversion. Results: The median decrease in HBV DNA at week 96 was higher in the combination group (-5.30 vs. -3.98 log 10 copies/ml, p = 0.05). More patients in the combination group had normalization of alanine aminotransaminase and HBV DNA < 300 copies/ml at week 96 when compared with the monotherapy group [11 of the 14 patients (78.6%) vs. 6 of the 16 patients (37.5%), p = 0.03]. However, HBeAg seroconversion at week 96 was similar in the 2 groups [2/14 (14.3%) vs. 4/16 (25.0%), p = NS]. No ADV or FTC resistance was detected at week 96. In those with HBeAg seroconversion, 50.0% had post-treatment relapse. Conclusions: Combination ADV plus FTC resulted in more potent suppression of HBV DNA over 96 weeks of therapy. © 2008 European Association for the Study of the Liver.
Persistent Identifierhttp://hdl.handle.net/10722/157512
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHui, CKen_US
dc.contributor.authorZhang, HYen_US
dc.contributor.authorBowden, Sen_US
dc.contributor.authorLocarnini, Sen_US
dc.contributor.authorLuk, JMen_US
dc.contributor.authorLeung, KWen_US
dc.contributor.authorYueng, YHen_US
dc.contributor.authorWong, Aen_US
dc.contributor.authorRousseau, Fen_US
dc.contributor.authorYuen, KYen_US
dc.contributor.authorNaoumov, NNen_US
dc.contributor.authorLau, GKKen_US
dc.date.accessioned2012-08-08T08:50:45Z-
dc.date.available2012-08-08T08:50:45Z-
dc.date.issued2008en_US
dc.identifier.citationJournal Of Hepatology, 2008, v. 48 n. 5, p. 714-720en_US
dc.identifier.issn0168-8278en_US
dc.identifier.urihttp://hdl.handle.net/10722/157512-
dc.description.abstractBackground/Aims: In order to prevent the occurrence of drug-resistant mutants associated with treatment for chronic hepatitis B virus (HBV) infection, combination therapy is being developed. To determine the efficacy of adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy in chronic HBV infection. Methods: Thirty treatment-nai{dotless}̈ve, HBeAg-positive patients were randomized to combination ADV plus FTC (n = 14) or ADV plus placebo monotherapy (n = 16) for 96 weeks. HBV DNA was measured by polymerase chain reaction. Treatment was stopped in those with HBeAg seroconversion. Results: The median decrease in HBV DNA at week 96 was higher in the combination group (-5.30 vs. -3.98 log 10 copies/ml, p = 0.05). More patients in the combination group had normalization of alanine aminotransaminase and HBV DNA < 300 copies/ml at week 96 when compared with the monotherapy group [11 of the 14 patients (78.6%) vs. 6 of the 16 patients (37.5%), p = 0.03]. However, HBeAg seroconversion at week 96 was similar in the 2 groups [2/14 (14.3%) vs. 4/16 (25.0%), p = NS]. No ADV or FTC resistance was detected at week 96. In those with HBeAg seroconversion, 50.0% had post-treatment relapse. Conclusions: Combination ADV plus FTC resulted in more potent suppression of HBV DNA over 96 weeks of therapy. © 2008 European Association for the Study of the Liver.en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhepen_US
dc.relation.ispartofJournal of Hepatologyen_US
dc.rightsJournal of Hepatology. Copyright © Elsevier BV.-
dc.subjectAdefovir dipivoxil-
dc.subjectAdefovir dipivoxil plus emtricitabine-
dc.subjectCombination therapy-
dc.subjectNormalization of serum alanine aminotransaminase-
dc.subjectSerum HBV DNA suppression-
dc.subject.meshAdenine - Administration & Dosage - Adverse Effects - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshAdulten_US
dc.subject.meshAlanine Transaminase - Blooden_US
dc.subject.meshAntiviral Agents - Therapeutic Useen_US
dc.subject.meshDna, Viral - Blooden_US
dc.subject.meshDeoxycytidine - Administration & Dosage - Adverse Effects - Analogs & Derivativesen_US
dc.subject.meshDrug Resistance, Viralen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B E Antigens - Blooden_US
dc.subject.meshHepatitis B, Chronic - Drug Therapy - Virologyen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPhosphonic Acids - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.title96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis Ben_US
dc.typeArticleen_US
dc.identifier.emailLuk, JM:jmluk@hkucc.hku.hken_US
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_US
dc.identifier.authorityLuk, JM=rp00349en_US
dc.identifier.authorityYuen, KY=rp00366en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.jhep.2007.10.013en_US
dc.identifier.pmid18207280-
dc.identifier.scopuseid_2-s2.0-40849132370en_US
dc.identifier.hkuros141320-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-40849132370&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume48en_US
dc.identifier.issue5en_US
dc.identifier.spage714en_US
dc.identifier.epage720en_US
dc.identifier.isiWOS:000255425100006-
dc.publisher.placeNetherlandsen_US
dc.identifier.scopusauthoridHui, CK=35082057900en_US
dc.identifier.scopusauthoridZhang, HY=8965962000en_US
dc.identifier.scopusauthoridBowden, S=7005525615en_US
dc.identifier.scopusauthoridLocarnini, S=35953095500en_US
dc.identifier.scopusauthoridLuk, JM=7006777791en_US
dc.identifier.scopusauthoridLeung, KW=23097859100en_US
dc.identifier.scopusauthoridYueng, YH=8965962100en_US
dc.identifier.scopusauthoridWong, A=23098949400en_US
dc.identifier.scopusauthoridRousseau, F=7102890512en_US
dc.identifier.scopusauthoridYuen, KY=36078079100en_US
dc.identifier.scopusauthoridNaoumov, NN=23098212400en_US
dc.identifier.scopusauthoridLau, GKK=7102301257en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats